淋巴畸形市場：現況分析與預測（2023-2030）

由於疾病治療方法的發展取得進展，全球淋巴畸形市場規模預計將穩定成長約6.54%。 例如，2023 年 11 月，Palvella Therapeutics, Inc. 的 QTORIN 雷帕黴素用於治療微囊性淋巴畸形，獲得了美國食品和藥物管理局 (FDA) 的突破性療法認定。 在預測期內，多種因素正在推動市場成長，例如對淋巴畸形的認識提高和醫療保健領域投資的增加。 除此之外，淋巴畸形治療效率的加速帶來了有效的治療程序，也推動了淋巴畸形市場的穩定發展。

根據應用，市場分為診斷和治療。 由於淋巴管畸形病例數量不斷增加，到2022年，診斷領域將佔據全球淋巴管畸形市場的最大佔有率。 因此，對診斷工具和服務的需求不斷增長，以篩檢和監測患者的此類併發症。 糖尿病視網膜病變市場以診斷領域為主，因為醫療保健系統優先考慮早期檢測和乾預，以促進受淋巴管畸形影響的患者的福祉。 技術創新、篩檢項目的擴大以及新興國家的市場擴張可能會在未來幾年進一步推動這一領域的成長。 因此，從應用來看，診斷領域將在2022年佔據較大的市場佔有率。

根據最終用戶，市場分為醫院、診所和其他。 由於人們對淋巴畸形的認識不斷提高，預計診所部分將在預測期內佔據重要的市場佔有率。 診所通常作為提高患者和醫療保健專業人員對淋巴畸形認識的中心。 隨著意識的提高，更多的患者尋求診斷和治療，診所就診次數也隨之增加。 診所配備了超音波、MRI、淋巴閃爍掃瞄等先進的診斷工具和技術，可準確診斷淋巴管畸形。 透過提供個人化的治療計劃和支援服務，他們優先考慮以患者為中心的護理，並傾向於吸引更多患者。 因此，在預測期內，診所類別在最終用戶中將表現出更高的複合年增長率。

為了更瞭解淋巴管畸形的市場介紹，市場為北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國） 、日本）、印度、亞太地區其他地區）以及世界其他地區。 由於淋巴畸形病例迅速增加、人們對淋巴畸形的認識不斷提高以及引入創新治療的舉措和投資不斷增加，北美在 2022 年目前的情況下將主導市場。 例如，總部位於美國的 Protara Therapeutics 於 2023 年 10 月在其 II 期 STARBORN-1 試驗中開始給藥，該試驗旨在研究一種治療兒科患者淋巴管畸形的潛在細胞療法。 由於該地區病例數量不斷增加，政府機構啟動了淋巴畸形認識計畫。 因此，依地區劃分，北美將在 2022 年佔據較大市場佔有率。

市場的主要營運公司包括 Pfizer Inc.、Protara Therapeutics、Zydus Pharmaceuticals, Inc.、Palvella Therapeutics、Avalo Therapeutics, Inc.、Alkem Laboratories Ltd. 和 GLENMARK PHARMACEUTICALS LTD。

目錄

第一章市場介紹

• 市場定義
• 主要目標
• 利害關係人
• 限制

第二章研究方法/先決條件

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章COVID-19對淋巴畸形市場的影響

第 6 章淋巴畸形市場收入，2020-2030

第 7 章市場洞察：依應用劃分

• 診斷
• 處理中

第 8 章市場洞察：最終用戶

• 醫院
• 診所
• 其他

第 9 章市場洞察：依地區

• 北美
  • 美國
  • 加拿大
  • 北美其他地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 亞太地區其他地區
• 其他領域

第十章淋巴畸形市場動態

• 市場驅動因素
• 市場問題
• 影響分析

第11章淋巴畸形的市場機會

第十二章淋巴畸形市場趨勢

第十三章供需分析

• 需求方分析
• 供給面分析

第14章價值鏈分析

第15章競爭場景

• 競爭狀況
  • 波特五力分析

第十六章公司概況

• Pfizer Inc.
• Protara Therapeutics
• Zydus Pharmaceuticals, Inc.
• Palvella Therapeutics
• Avalo Therapeutics, Inc.
• Alkem Laboratories Ltd.
• GLENMARK PHARMACEUTICALS LTD.

第十七章免責聲明

Lymphatic malformations are a form of rare disorders which are non-malignant masses consisting of fluid-filled channels due to abnormal development of lymphatic systems. These malformations are usually seen in the head and neck region of the body. Lymphatic malformations can be massive in size and even smaller malformations can potentially cause functional impairment of nearby organs and disfigurement of affected areas. Innovations in drug development and a rising number of clinical trials are leading to the growth of the market. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are also acting as drivers of lymphatic malformation globally.

The Lymphatic Malformations Market is expected to grow at a steady rate of around 6.54% owing to the rising therapeutic developments for treating the illness. For instance, in November 2023, Palvella Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation to QTORIN rapamycin for the treatment of microcystic lymphatic malformations. Several factors, including increasing awareness regarding lymphatic malformation, and increased investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, accelerated treatment efficiency of lymphatic malformation has resulted in effective treatment procedures which are also driving this market of lymphatic malformation at a steady rate.

Based on the application, the market is bifurcated into diagnosis and treatment. The diagnosis segment held the maximum share in the global market of lymphatic malformation in 2022 owing to the rising cases of lymphatic malformation. As a result, there is a growing demand for diagnostic tools and services to screen and monitor patients for such complications. The diagnosis segment in the diabetic retinopathy market dominated as healthcare systems prioritize early detection and intervention for the welfare of patients suffering from lymphatic malformations. Technological innovations, expanding screening programs, and market expansion in emerging economies will further drive the growth of this segment in the coming years. Thus, among the applications, the diagnosis segment held a significant market share in 2022.

Based on the end user, the market is categorized into hospitals, clinics, and others. The clinic segment is expected to hold a significant share of the market in the forecast period owing to the rising awareness regarding lymphatic malformations. Clinics often serve as hubs for raising awareness about lymphatic malformations among patients and healthcare professionals. As awareness increases, more patients seek diagnosis and treatment, leading to growth in clinic visits. They are equipped with advanced diagnostic tools and techniques, such as ultrasound, MRI, and lymphoscintigraphy, which can accurately diagnose lymphatic malformations. It prioritizes patient-centered care by offering personalized treatment plans and supportive services tends to attract more patients. Thus, the clinic category will witness a higher CAGR amongst end users during the forecast period.

For a better understanding of the market adoption of lymphatic malformation, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the surge in cases of lymphatic malformation, rising awareness about lymphatic malformation, and rising initiatives and investments in introducing innovative therapies. For instance, in October 2023, U.S.-based Protara Therapeutics commenced dosing in its Phase II STARBORN-1 trial investigating its cell therapy candidate for the treatment of lymphatic malformations in pediatric patients. Government organizations are initiating lymphatic malformation awareness programs for the sake of the growing cases in the region. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include Pfizer Inc.; Protara Therapeutics; Zydus Pharmaceuticals, Inc.; Palvella Therapeutics; Avalo Therapeutics, Inc.; Alkem Laboratories Ltd.; GLENMARK PHARMACEUTICALS LTD.

TABLE OF CONTENTS

1MARKET INTRODUCTION

• 1.1.Market Definitions
• 1.2.Main Objective
• 1.3.Stakeholders
• 1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1.Research Process of the Lymphatic Malformations Market
• 2.2.Research Methodology of the Lymphatic Malformations Market
• 2.3.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE LYMPHATIC MALFORMATIONS MARKET

6LYMPHATIC MALFORMATIONS MARKET REVENUE (USD BN), 2020-2030F

7MARKET INSIGHTS BY APPLICATION

• 7.1.Diagnosis
• 7.2.Treatment

8MARKET INSIGHTS BY END USER

• 8.1.Hospitals
• 8.2.Clinics
• 8.3.Others

9MARKET INSIGHTS BY REGION

• 9.1.North America
  • 9.1.1.U.S.
  • 9.1.2.Canada
  • 9.1.3.Rest of North America
• 9.2.Europe
  • 9.2.1.Germany
  • 9.2.2.U.K.
  • 9.2.3.France
  • 9.2.4.Italy
  • 9.2.5.Spain
  • 9.2.6.Rest of Europe
• 9.3.Asia-Pacific
  • 9.3.1.China
  • 9.3.2.Japan
  • 9.3.3.India
  • 9.3.4.Rest of Asia-Pacific
• 9.4.Rest of World

10LYMPHATIC MALFORMATIONS MARKET DYNAMICS

• 10.1.Market Drivers
• 10.2.Market Challenges
• 10.3.Impact Analysis

11LYMPHATIC MALFORMATIONS MARKET OPPORTUNITIES

12LYMPHATIC MALFORMATIONS MARKET TRENDS

13DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1.Demand Side Analysis
• 13.2.Supply Side Analysis

14VALUE CHAIN ANALYSIS

15COMPETITIVE SCENARIO

• 15.1.Competitive Landscape
  • 15.1.1.Porters Fiver Forces Analysis

16COMPANY PROFILED

• 16.1.Pfizer Inc.
• 16.2.Protara Therapeutics
• 16.3.Zydus Pharmaceuticals, Inc.
• 16.4.Palvella Therapeutics
• 16.5.Avalo Therapeutics, Inc.
• 16.6.Alkem Laboratories Ltd.
• 16.7.GLENMARK PHARMACEUTICALS LTD.

17DISCLAIMER